Cell Line Development (CLD) 2.0

6th July 2017

Category: Cell Line Development

Tags: ,

By: Caroline Hauser - Team Leader, Dr Christoph Zehe - Head of Technology Development, Juliana Schubert - Scientist, Kristin Thiele - Scientist,

The production of biologics in Chinese Hamster Ovary cells (CHO) is becoming more and more challenging due to an increasing number of complex and difficult-to-express (DTE) molecules. Nevertheless, general Cell Line Development (CLD) platform processes should provide reliable high-titer cell lines irrespective of the therapeutic protein formats to be expressed. In the last 20 years More

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.